此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

先兆子痫干预荷兰 (PI-NL)

2026年11月2日 更新者:Dr Rebecca C. Painter、Amsterdam UMC

二甲双胍用于延长早产先兆子痫的妊娠

The goal of this study is to find out if pregnant individuals with preterm preeclampsia (PE) who are treated with metformin can stay pregnant for longer, and if this is safe(r) for the mother and child. Preterm PE affects about 1 in 100 pregnant individuals in the Netherlands. Signs of preterm PE can be high blood pressure and protein in the urine in the second half of pregnancy (but before 32-34 weeks of pregnancy). Other symptoms can develop, such as problems with blood clotting and how well the blood cells, liver, lungs, and brain work. The disease can lead to serious complications for both the mother and child. The only way to cure preterm PE is to make sure the child is born, and many times, children have to be delivered (very) early (before 37 weeks). Children born (very) early can suffer from infections, breathing difficulties, and problems in their development.

Metformin is a medicine used to treat high blood sugar during and outside of pregnancy. In a previous study in South Africa, women with preterm PE that used metformin were able to safely remain pregnant for an extra week. Similarly, the main goal of the Preeclampsia Intervention NetherLands (PI-NL) study is to see if patients with preterm PE in the Netherlands that use metformin can remain pregnant for a longer time than patients taking a placebo. A placebo is a look-a-like capsule that contains no active ingredients. Researchers, the treating medical team, and participants will not know which participant gets which treatment. In addition, all participants will receive the standard care that all preterm PE patients get.

研究概览

详细说明

Preterm preeclampsia (PE) is a severe hypertensive disorder of pregnancy and a major cause of maternal and perinatal morbidity and mortality. Currently, the only treatment to halt disease progression is delivery of the dysfunctional placenta and thereby the child. This often happens prematurely. Being able to safely (for mother and child) extend pregnancy, even by a few days, is expected to reduce the short- and long-term risks associated with (severe) prematurity. Preclinical and recent clinical evidence presents metformin, a drug commonly used to treat diabetes in and outside of pregnancy, as a promising treatment candidate for preterm PE. Metformin might reduce inflammation, oxidative stress, and anti-angiogenesis, and improve endothelial function. In a recent South African trial, use of metformin was associated with a safe median 7.6 day prolongation of pregnancy in women with preterm PE, compared to placebo. There was a nonsignificant increase in the neonatal birthweight and a decrease in the length of stay in any neonatal nursery. Metformin did not lead to any serious adverse events.

The goal of this multicenter, triple-blind, randomized placebo-controlled trial is to investigate whether metformin can safely prolong gestation in patients with preterm PE in the Dutch population. Secondary outcomes include composite adverse maternal, fetal, and neonatal outcomes. Cost-effectiveness of the treatment will be evaluated.

研究类型

介入性

注册 (估计的)

180

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

      • Amsterdam、荷兰
        • 招聘中
        • Amsterdam UMC
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 50年 (成人)

接受健康志愿者

不

有资格学习的性别

女性

描述

Inclusion Criteria

All of the following:

  • Aged 18 years or older
  • Singleton pregnancy
  • Gestational age between 23+0 and 31+6 weeks
  • A diagnosis of preterm preeclampsia, defined according to modified International Society for the Study of Hypertension in Pregnancy (ISSHP) classification, including only those who have proteinuria (≥300 mg of protein in a 24-hour urine specimen or a protein-creatinine-ratio >50 in a single urine sample)
  • Estimated fetal weight >400 grams
  • No clear indication (maternal or fetal) or intention, by both the treating multidisciplinary team and the patient after counseling, to immediately deliver (or directly after corticosteroid administration) or to terminate the pregnancy otherwise.
  • Ability to understand English or Dutch
  • Ability and willingness to provide written informed consent

Exclusion Criteria

Any of the following:

  • Current use of metformin or a clinical indication for the use of metformin
  • A decision for immediate delivery (including cases where corticosteroids are administered with planned delivery directly after completion of treatment) or termination of pregnancy (e.g., due to disease severity in the patient combined with a dismal prognosis for the fetus), as made by the treating multidisciplinary team and the parent(s)
  • Contraindication(s) for the use of metformin (e.g., severe renal insufficiency, acute metabolic acidosis, severe liver insufficiency)
  • Use of drugs that might interact with metformin
  • Suspicion of a major fetal anomaly and/or chromosomal abnormality
  • Unable or unwilling to (completely) understand or provide informed consent, due to language, culture, or other barriers

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:Metformin

Metformin 3000 mg divided by three daily doses (3 times 2 capsules of 500 mg; following a step-up schedule) from randomization till delivery, aside from usual preterm preeclampsia care.

Metformin Hydrochloride encapsulated immediate-release tablet of 500 mg, backfilled with cellulose.

其他名称:
  • 二甲双胍
  • 盐酸二甲双胍
安慰剂比较:Placebo

Placebo, divided by three daily doses (3 times 2 capsules; following a step-up schedule) from randomization till delivery, aside from usual preterm preeclampsia care.

Capsule filled with cellulose.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Number of days between randomization and delivery
大体时间:Time between randomization and delivery (up to 37 weeks of gestation)

Prolongation of gestation

Time between randomization and delivery (up to 37 weeks of gestation)

次要结果测量

结果测量
措施说明
大体时间
Number of participants reaching a composite maternal adverse outcome
大体时间:Randomization till 90 days postpartum (unless otherwise specified)

Combined endpoint of maternal death (during pregnancy or within 42 days postpartum), eclampsia, pulmonary edema, severe renal impairment, cerebrovascular accident, placental abruption, and/or liver hematoma or rupture.

Randomization till 90 days postpartum (unless otherwise specified)
Number of participants reaching a composite fetal adverse outcome
大体时间:Randomization till delivery (up to 37 weeks of gestation)

Combined endpoint of intrauterine fetal demise, suboptimal fetal condition based on CTG, and fetal growth restriction.

Randomization till delivery (up to 37 weeks of gestation)
Number of participants reaching a composite neonatal adverse outcome
大体时间:Birth till 90 days after birth (unless otherwise specified)

Combined endpoint of neonatal death (within 28 days after birth), grade 3 or 4 intraventricular hemorrhage, retinopathy of prematurity requiring treatment, necrotizing enterocolitis (grade II or higher), bronchopulmonary dysplasia, neonatal sepsis, and cystic periventricular leukomalacia (grade II or higher)

Birth till 90 days after birth (unless otherwise specified)

其他结果措施

结果测量
措施说明
大体时间
Maternal individual exploratory outcomes
大体时间:Randomization till 90 days postpartum (unless otherwise specified)

Number of participants experiencing each of the following: maternal death, cerebrovascular event, eclampsia, cortical blindness, pulmonary edema, AKI, liver hematoma/rupture, placental abruption, retinal detachment, postpartum hemorrhage, HELLP syndrome, severe elevated liver enzymes, low platelets, left ventricular heart failure, PRES, DIC, thromboembolic disease, need for dialysis due to renal failure, admission to high or ICU, need for intubation and mechanical ventilation

Randomization till 90 days postpartum (unless otherwise specified)
Fetal individual exploratory outcomes
大体时间:Randomization till 90 days postpartum (unless otherwise specified)

Number of participants experiencing each of the following: intrauterine or intrapartum fetal death, reversed end diastolic flow in umbilical artery on at least 2 occasions, redistribution in the middle cerebral artery, absent or reversed a-wave in ductus venosus, suboptimal fetal condition based on CTG.

Randomization till 90 days postpartum (unless otherwise specified)
Neonatal individual exploratory outcomes
大体时间:Randomization till 90 days postpartum (unless otherwise specified)

Number of participants experiencing each of the following: neonatal death within 28 days after birth, neonatal death between 29 and 90 days after birth, growth restriction at birth, Apgar score < 7 at 5 min, umbilical artery pH < 7.10, neonatal hypoglycemia, neonatal seizures, intraventricular hemorrhage, necrotizing enterocolitis, retinopathy of the premature, pulmonary insufficiency of the preterm infant, bronchopulmonary dysplasia, cystic periventricular leukomalacia, patent ductus arteriosus, persistent pulmonary hypertension, surfactant use within 72 hours after birth, need for respiratory support, admission to NICU.

Randomization till 90 days postpartum (unless otherwise specified)
Mean neonatal birthweight
大体时间:Within the first 24 hours after birth

In grams

Within the first 24 hours after birth
Median neonatal length of stay in any neonatal nursery, including NICU
大体时间:Birth till 90 days postpartum

In days

Birth till 90 days postpartum
Incremental cost-effectiveness ratios (ICERs; exploratory)
大体时间:Start of pregnancy till 90 days postpartum

Determined through length of maternal stay in hospital (and specifically ICU), neonatal length of stay in hospital (and specifically NICU), other health care utilization (based on iMCQ questionnaire, maternal and neonatal use of medication during pregnancy and after birth), loss of productivity (measured with iPCQ questionnaire), quality-of-life (score on EQ-5D-5L).

Start of pregnancy till 90 days postpartum
Rate of diarrhea, nausea/vomiting, abdominal pain, headache (all based on PHASE-20 questionnaire), lactic acidosis, and hypoglycemia (individually)
大体时间:Randomization till delivery (up to 37 weeks of gestation)

Tolerability and safety of metformin

Randomization till delivery (up to 37 weeks of gestation)
Score on PROMIS Anxiety 8a Short Form
大体时间:Randomization till 90 days postpartum

Maternal anxiety

Randomization till 90 days postpartum
Score on EPDS
大体时间:Randomization till 90 days postpartum

Maternal depressive symptoms

Randomization till 90 days postpartum
Score on Rosenberg Self-Esteem Scale
大体时间:Randomization till 90 days postpartum

Maternal self-esteem

Randomization till 90 days postpartum
Score on City Birth Trauma Scale
大体时间:Randomization till 90 days postpartum

Childbirth-related PTSD

Randomization till 90 days postpartum

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 首席研究员:R.C. Painter, Prof, MD, PhD、Amsterdam UMC

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年9月19日

初级完成 (估计的)

2029年3月19日

研究完成 (估计的)

2029年6月19日

研究注册日期

首次提交

2024年5月31日

首先提交符合 QC 标准的

2024年6月5日

首次发布 (实际的)

2024年6月11日

研究记录更新

最后更新发布 (实际的)

2026年11月4日

上次提交的符合 QC 标准的更新

2026年11月2日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

The investigators plan to collaborate with researchers of the international Preeclampsia Intervention (PI) trials.

IPD 共享时间框架

T.b.d.

IPD 共享访问标准

The results of the IPD will be published in a peer-reviewed journal.

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 分析代码
  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅